Newsroom | 70334 results

BOCA RATON, Fla.--(BUSINESS WIRE)--Cataltheia Group e la sua controllata statunitense, Bruno Vision Care LLC, azienda leader nell'innovazione della salute degli occhi, oggi hanno annunciato che la loro tecnologia di lente a contatto monouso giornaliera ad aumentata profondità di fuoco (EDOF) per la presbiopia Deseyne® è stata premiata quest'anno con il premio “Best New Technology Solution - Ophthalmology” ai 2026 MedTech Breakthrough Awards. Il programma MedTech Breakthrough Awards riconosce le...

HASLET, Texas--(BUSINESS WIRE)--Davidson Bogel Real Estate (DB2RE) is pleased to announce the sale of approximately 7 acres of land located at the southwest corner of Haslet Parkway and Harmon Road in Haslet, Texas. Collins Meier, Ryan Turner, David Davidson, Jr., and Edward Bogel represented the seller in the transaction. The buyer, Encompass Health, partnered closely with the land owner and master developer, Terra Manna, to bring the project to fruition. JLL represented the buyer in the trans...

MIAMI--(BUSINESS WIRE)--Coolibar, the world’s leading UPF 50+ sun protection apparel brand, is continuing its partnership with skin cancer survivor and advocate Dayanara Torres and the Melanoma Research Foundation (MRF) for Skin Cancer Awareness Month this May. The 2026 campaign brings a more intimate and elevated creative direction to Coolibar’s sun safety message, using emotional storytelling to encourage prevention, protection, and early detection. Together, the partners aim to reach communi...

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced the presentation of initial clinical data from the first participant dosed in its Phase 1/2 trial of EN-374 for the treatment of X-linked chronic granulomatous disease (X-CGD) at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11-15 in Boston. The data represent the first reported clini...

MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ: TBRG) (“TruBridge”), a leading provider of healthcare technology solutions for rural and community hospitals, today announced financial results for the first quarter ended March 31, 2026. Recent Developments As previously announced on April 23, 2026, TruBridge announced a definitive agreement whereby TruBridge, Inc. will be acquired by Inventurus Knowledge Solutions, Inc. (“IKS”), the U.S. subsidiary of Inventurus Knowledge Solutions Limit...

LOS ANGELES--(BUSINESS WIRE)--Saban Community Clinic (SCC) today breaks ground on its new Crenshaw Family Health Center, a major expansion that will bring comprehensive, community-based healthcare to the heart of South Los Angeles, one of the most underserved regions in Los Angeles County. The new facility is located in the historic Crenshaw Corridor and will serve a community where more than 287,000 low-income residents face limited access to primary care. The project directly addresses longst...

BOCA RATON, Fla.--(BUSINESS WIRE)--Bruno Vision Care's FDA-cleared Deseyne® Extended Depth of Focus daily disposable contact lens for presbyopia wins 2026 MedTech Breakthrough Award....

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement (the “Garda Agreement”) to be acquired by Garda for $21.80 per shar...

PRINCETON, N.J.--(BUSINESS WIRE)--Kanvas Biosciences, a full-stack spatial biology and microbial therapeutics company, today announced a new investment from Gates Foundation. Through this investment, Kanvas will develop the world’s first fully synthetic microbiome replacement product designed to treat and prevent maternal environmental enteric dysfunction (EED), a major contributor to maternal undernutrition, low infant birthweight and heightened neonatal health risk. Using global metagenomic d...

SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced the initiation of the KYRON Phase 1b/2 clinical trial of ABS-1230 for the treatment of KCNT1-related epilepsy, a rare, severe and often fatal pediatric developmental epileptic encephalopathy. ABS-1230 is designed to be a potent and selective orally available small molecule KCNT1 inhibitor that addresses the underlying...